Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sugalife-S
- Development stage
- Phase 4
- Lead developer
- Intra Life
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Sugalife-S** is an oral fixed-dose antidiabetic tablet marketed by Intra Life for **type 2 diabetes mellitus in adults**. It combines sustained-release gliclazide 60 mg, a sulfonylurea that promotes pancreatic beta-cell insulin secretion through ATP-sensitive potassium-channel closure, with sitagliptin 100 mg, a dipeptidyl peptidase-4 inhibitor that prolongs incretin activity to increase glucose-dependent insulin secretion and suppress glucagon. The product is intended to improve glycemic control when diet, exercise, or monotherapy are insufficient.
- Brand names
- Sugalife-S
- Other names
- gliclazide + sitagliptin
02
Targets
KATP channel (ATP-sensitive potassium channel)DPP-4 (Dipeptidyl Peptidase-IV)SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on Sugalife-S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sugalife-S.